{"id":42485,"date":"2018-11-19T21:08:15","date_gmt":"2018-11-19T19:08:15","guid":{"rendered":"https:\/\/newserver.fyb.de\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/"},"modified":"2018-11-19T21:08:15","modified_gmt":"2018-11-19T19:08:15","slug":"37-million-euro-round-gimv-invests-in-biotech-company-camel-ids","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/","title":{"rendered":"37 million euro round: Gimv invests in biotech company Camel-IDS"},"content":{"rendered":"<p>Antwerp (BE) \u2014 Brussels-based <strong>Camel-IDS<\/strong>, which is deve\u00adlo\u00adping novel radio\u00adim\u00admu\u00adno\u00adthe\u00adrapy drugs to treat cancer, has closed a<strong> \u20ac37 million<\/strong> Series A finan\u00adcing round \u2014 making it one of the larger rounds among early-stage life scien\u00adces compa\u00adnies in Europe. Euro\u00adpean private equity firm<strong> Gimv<\/strong> is the <strong>lead inves\u00adtor<\/strong> toge\u00adther with <strong>V\u2011Bio Ventures<\/strong>, contri\u00adbu\u00adting six million euros. Other inves\u00adtors include <strong>Health\u00adCap, Novo Seeds, Ponti\u00adfax and BioMed\u00adPart\u00adners<\/strong>. With the new capi\u00adtal, Camel-IDS plans to conduct a Phase Ib\/II clini\u00adcal trial for its lead deve\u00adlo\u00adp\u00adment candi\u00addate in breast cancer with brain meta\u00adsta\u00adses, as well as further expand its pre-clini\u00adcal pipeline.<\/p>\n<p>Camel-IDS (www.camel-ids.com) was foun\u00added in 2014 as a spin-off of the Vrije Univer\u00adsi\u00adteit Brussel (VUB). The company deve\u00adlops novel radio\u00adphar\u00admaceu\u00adti\u00adcals based on single domain anti\u00adbo\u00addies linked to radi\u00ado\u00adnu\u00adcli\u00addes. Pati\u00adents with breast cancer whose tumors have an eleva\u00adted presence of the growth-promo\u00adting HER2 onco\u00adpro\u00adtein can now be trea\u00adted effec\u00adtively and speci\u00adfi\u00adcally, but their progno\u00adsis is extre\u00admely poor if the cancer spreads to the brain. The most advan\u00adced deve\u00adlo\u00adp\u00adment candi\u00addate of Camel-IDS starts there: It is inten\u00added to irra\u00addiate corre\u00adspon\u00adding brain lesi\u00adons effec\u00adtively and without harming healthy tissue. This is based on a unique tech\u00adno\u00adlogy plat\u00adform that takes advan\u00adtage of the favorable tissue distri\u00adbu\u00adtion of single domain anti\u00adbo\u00addies asso\u00adcia\u00adted with radi\u00ado\u00adnu\u00adcli\u00addes, as found in camelids.<\/p>\n<p><strong>Karl N\u00e4gler (photo)<\/strong>, <strong>Part\u00adner of Gimv\u2019s Health &amp; Care plat\u00adform<\/strong>., explains: \u201cIn our discus\u00adsions, the great compe\u00adtence of the Camel-IDS team in the field of radio-immu\u00adno\u00adthe\u00adrapy and the excep\u00adtio\u00adnal exper\u00adtise of Profes\u00adsor Tony Lahoutte became appa\u00adrent early on. With CEO Ruth Deve\u00adnyns, the company also has an accom\u00adplished connois\u00adseur of the Euro\u00adpean biotech market and a successful entre\u00adpre\u00adneur. These are the best prere\u00adqui\u00adsi\u00adtes for the next stage of development.\u201d<\/p>\n<p>Gimv\u2019s commit\u00adment is the company\u2019s fourth invest\u00adment this year in the life scien\u00adces, medi\u00adcal tech\u00adno\u00adlogy and health\u00adcare sectors and unders\u00adcores Gimv\u2019s role as one of the most active inves\u00adtors in the Euro\u00adpean health\u00adcare indus\u00adtry. This brings the number of port\u00adfo\u00adlio compa\u00adnies in Gimv\u2019s Health &amp; Care plat\u00adform to&nbsp;21.<\/p>\n<p><strong>About Gimv<\/strong><br>\nGimv is a Euro\u00adpean invest\u00adment firm with nearly 40 years of expe\u00adri\u00adence in private equity and venture capi\u00adtal. The company is listed on Euron\u00adext Brussels, curr\u00adently mana\u00adges around EUR 1.6 billion and curr\u00adently invests in around 50 port\u00adfo\u00adlio compa\u00adnies, which toge\u00adther gene\u00adrate reve\u00adnues of more than EUR 2.5 billion and employ more than 14,000 people.<\/p>\n<p>Gimv iden\u00adti\u00adfies inno\u00adva\u00adtive, leading compa\u00adnies with high growth poten\u00adtial and supports them on their way to market leader\u00adship. Each of the four invest\u00adment plat\u00adforms Connec\u00adted Consu\u00admer, Health &amp; Care, Smart Indus\u00adtries and Sustainable Cities is mana\u00adged by a dedi\u00adca\u00adted and compe\u00adtent team, each based in Gimv\u2019s home markets \u2014 Bene\u00adlux, France and DACH \u2014 and supported by an exten\u00adsive inter\u00adna\u00adtio\u00adnal network of experts.<br>\nFor more infor\u00adma\u00adtion about Gimv, visit www.gimv.com.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antwerp (BE) \u2014 Brussels-based Camel-IDS, which is deve\u00adlo\u00adping novel radio\u00adim\u00admu\u00adno\u00adthe\u00adrapy drugs to treat cancer, has closed a \u20ac37 million Series A finan\u00adcing round \u2014 making it one of the larger rounds among early-stage life scien\u00adces compa\u00adnies in Europe. Euro\u00adpean private equity firm Gimv is the lead inves\u00adtor toge\u00adther with V\u2011Bio Ventures, contri\u00adbu\u00adting six million euros.&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42499,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>37 million euro round: Gimv invests in biotech company Camel-IDS - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"37 million euro round: Gimv invests in biotech company Camel-IDS - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Antwerp (BE) \u2014 Brussels-based Camel-IDS, which is deve\u00adlo\u00adping novel radio\u00adim\u00admu\u00adno\u00adthe\u00adrapy drugs to treat cancer, has closed a \u20ac37 million Series A finan\u00adcing round \u2014 making it one of the larger rounds among early-stage life scien\u00adces compa\u00adnies in Europe. Euro\u00adpean private equity firm Gimv is the lead inves\u00adtor toge\u00adther with V\u2011Bio Ventures, contri\u00adbu\u00adting six million euros. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-19T19:08:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png\" \/>\n\t<meta property=\"og:image:width\" content=\"270\" \/>\n\t<meta property=\"og:image:height\" content=\"212\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"37 million euro round: Gimv invests in biotech company Camel-IDS\",\"datePublished\":\"2018-11-19T19:08:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\",\"url\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\",\"name\":\"37 million euro round: Gimv invests in biotech company Camel-IDS - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png\",\"datePublished\":\"2018-11-19T19:08:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png\",\"width\":270,\"height\":212},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"37 million euro round: Gimv invests in biotech company Camel-IDS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"37 million euro round: Gimv invests in biotech company Camel-IDS - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/","og_locale":"en_US","og_type":"article","og_title":"37 million euro round: Gimv invests in biotech company Camel-IDS - FYB Financial Yearbook","og_description":"Antwerp (BE) \u2014 Brussels-based Camel-IDS, which is deve\u00adlo\u00adping novel radio\u00adim\u00admu\u00adno\u00adthe\u00adrapy drugs to treat cancer, has closed a \u20ac37 million Series A finan\u00adcing round \u2014 making it one of the larger rounds among early-stage life scien\u00adces compa\u00adnies in Europe. Euro\u00adpean private equity firm Gimv is the lead inves\u00adtor toge\u00adther with V\u2011Bio Ventures, contri\u00adbu\u00adting six million euros. [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-11-19T19:08:15+00:00","og_image":[{"width":270,"height":212,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"37 million euro round: Gimv invests in biotech company Camel-IDS","datePublished":"2018-11-19T19:08:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/","url":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/","name":"37 million euro round: Gimv invests in biotech company Camel-IDS - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png","datePublished":"2018-11-19T19:08:15+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/11\/a-nacc88gler-e1542654419935.png","width":270,"height":212},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/37-million-euro-round-gimv-invests-in-biotech-company-camel-ids\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"37 million euro round: Gimv invests in biotech company Camel-IDS"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42485"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42485\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42499"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}